PERJETA™ (pertuzumab) is an exciting new breast cancer drug from Genentech, a leading California biotech company. It has been shown to extend the life of a breast cancer patient by up to 6 months!
It is very effective BUT it is very expensive, costing about $80,000 per patient treatment. Add this to the fact that it is often used in combination with Herception, which costs about $100,000 per patient treatment.
Genentech is making it easier for patients to afford PERJETA™ (pertuzumab) by subsidizing co-insurance with an outstanding drug coupon offer known as the Genentech BioOncology™ Co-pay Card. This valuable coupon is also valid for 8 other drugs :)
The way it works is that for patients with family incomes less than $150,000 per year, Genentech will pay for 80% of your out-of-pocket costs up to $4,000 per year. If your family income is more than $150,000 per year, they will pay up to $1,500 per year.
Click HERE to learn more about the Perjenta™ Printable Coupon Co-pay Card, as described above.
Click HERE to learn more about the Genentech BioOncology™ Co-pay Card, as described above.
See Also: Genentech BioOncology™ Co-pay Card for Avastin | Herceptin | Rituxan | Erivedge | Tarceva | Xeloda | Zelboraf.